Robbins LLP Is Investigating the Officers and Directors of Meridian Bioscience, Inc. (VIVO) on Behalf of Shareholders

Robbins LLP is investigating whether certain officers and directors of Meridian Bioscience, Inc. (NasdaqGS: VIVO) violated federal laws. Meridian, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide.

Meridian Subsidiary is Under Investigation for Inaccurate Lead Tests

On May 17, 2017, the U.S. Food and Drug Administration ("FDA") warned that lead tests made by Meridian's subsidiary, Magellan Diagnostics, may provide falsely low results. The FDA subsequently launched an investigation into the issue and inspected Magellan's facility, stating that evidence revealed that the company put patients at risk after it recognized that its tests could be inaccurate and failed to take appropriate steps to report the issue. On October 23, 2017, the FDA announced that it identified numerous violations of federal law, including marketing modified versions of the company's blood lead testing systems without the FDA's required clearance and failure to submit medical device reports to the FDA regarding discrepancies in test results. If Magellan fails to promptly correct its misdeeds, the FDA may take additional action, such as seizure, injunction, and civil monetary penalties.

Meridian Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003 or you can complete the form below and we will contact you directly.